- GlaxoSmithKline (GSK -0.4%) has submitted supplement marketing applications to the European Medicines Agency seeking approval to use Nucala (mepolizumab) to treat hypereosinophilic syndrome (HES), chronic rhinosinusitis with nasal polyps (CRSwNP) and eosinophilic granulomatosis with polyangiitis (EGPA).
- The IL-5 antagonist is currently approved in Europe as an add-on treatment for patients with severe eosinophilic asthma.
- The product accounted for almost 3% of the company's Q3 revenues.
- https://seekingalpha.com/news/3628355-glaxo-files-applications-in-europe-for-expanded-use-of-nucala
Thursday, October 29, 2020
Glaxo files applications in Europe for expanded use of Nucala
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.